Experimental eye research · 2026
Topical Rho kinase inhibitor rescues TRPV4 deficiency-induced an impairment of corneal epithelial wound healing by enhancing limbal stem cell proliferation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yasuda Shingo, Sumioka Takayoshi, Takada Yukihisa, Tamura Tadahiko, Miyajima Masayasu, Okada Yuka, Saika Shizuya
Аннотация
PURPOSE: Transient receptor potential vanilloid 4 (TRPV4), a mechanosensitive cation channel, is essential for cell proliferation in peripheral cornea during epithelial repair. We examined whether topical administration of a Rho kinase inhibitor, Y-27632, rescues impaired epithelial healing in TRPV4 knockout (KO) mice.
METHODS: TRPV4 KO mice underwent 2 mm corneal epithelial debridement and were topically treated every 6 h with Y-27632 or PBS. Epithelial closure was monitored by fluorescein staining. Cell proliferation was evaluated by BrdU incorporation. Corneal sensitivity was assessed with a Cochet-Bonnet aesthesiometer. TKE2 cells were cultured with TRPV4 inhibitor HC-067047, with or without Y-27632, and proliferation was measured by Alamar Blue assay.
RESULTS: Topical Y-27632 significantly accelerated wound closure in TRPV4 KO mice at 24 h post-debridement. The number of BrdU-positive cells was significantly more frequently observed in the peripheral, but not central, cornea of Y-27632-treated mice as compared with control mice. Corneal surface sensitivity was unchanged by topical Y-27632. Supplementation of Y-27632 upregulated TKE2 proliferation under TRPV4 inhibition-condition.
CONCLUSIONS: Topical Y-27632 rescues TRPV4 deficiency-induced impairment of epithelial repair by promoting proliferation of cells in peripheral epithelium, presumably epithelial stem cells. ROCK inhibition may represent a novel therapeutic options for refractory corneal epithelial disorders.
METHODS: TRPV4 KO mice underwent 2 mm corneal epithelial debridement and were topically treated every 6 h with Y-27632 or PBS. Epithelial closure was monitored by fluorescein staining. Cell proliferation was evaluated by BrdU incorporation. Corneal sensitivity was assessed with a Cochet-Bonnet aesthesiometer. TKE2 cells were cultured with TRPV4 inhibitor HC-067047, with or without Y-27632, and proliferation was measured by Alamar Blue assay.
RESULTS: Topical Y-27632 significantly accelerated wound closure in TRPV4 KO mice at 24 h post-debridement. The number of BrdU-positive cells was significantly more frequently observed in the peripheral, but not central, cornea of Y-27632-treated mice as compared with control mice. Corneal surface sensitivity was unchanged by topical Y-27632. Supplementation of Y-27632 upregulated TKE2 proliferation under TRPV4 inhibition-condition.
CONCLUSIONS: Topical Y-27632 rescues TRPV4 deficiency-induced impairment of epithelial repair by promoting proliferation of cells in peripheral epithelium, presumably epithelial stem cells. ROCK inhibition may represent a novel therapeutic options for refractory corneal epithelial disorders.